EGFR and metastatic colorectal cancer: This evolution of EGFR inhibitor therapy in the treatment of metastatic colorectal cancer has revealed the importance of identifying patient populations more likely to respond to novel biologic targeted agents in the early stages of their development, so as to avoid unnecessary exposure of patients to ineffective therapies.